Monoclonal Antibodies in Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 194
Special Issue Editor
Special Issue Information
Dear Colleagues,
The introduction of monoclonal antibodies (MoAbs) into clinical practice has significantly improved the prognosis of many hematological malignancies, representing a milestone in the field of precision medicine.
Used in monotherapy or, more often, in combination with chemotherapy, MoAbs are currently essential in the treatment of lymphoid neoplasms.
MoAbs are able to target specific cancer antigens, using direct or indirect immunological killing to address cytotoxic agents to neoplastic cells, to recruit and activate immune effector cells, and to antagonize cell exhaustion.
In this Special Issue, we would like to provide an overview of the biological basis and the current clinical use of MoAbs and of the optimal combination regimens and sequential schemes, with a look towards future therapeutic perspectives.
Dr. Donato Mannina
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- monoclonal antibodies
- immunotherapy
- drug immunoconiugates
- bispecific antibodies
- checkpoints inhibitors
- NHL
- HL
- CLL
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Next-generation therapies in Mantle cell Lymphoma (MCL): the evolving landscape in treatment of relapse/refractory after CAR-T cells
Authors: Lorenzo Comba; Rita Tavarozzi; Claudia Castellino; Elia Boccellato; Foglietta Myriam; Massaia Massimo; Alessia Castellino
Affiliation: 1. Hematology Unit, Santa Croce e Carle Hospital, Cuneo, Italy
2. University of Turin, Torino, Italy
3. Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Abstract: Mantle cell lymphoma (MCL) is a biological and clinical heterogeneous disease, with courses ranging from indolent cases to highly aggressive ones, with limited prognosis. Bruton Tyrosin Kynase Inhibitors (BTK-i), such as ibrutinib, ameliorated the outcome of relapse/refractory patients, but responses are usually quite short, requiring further treatments. In this setting, immunotherapy demonstrated to have a key role, first with chimeric antigen receptor (CAR)-T cells, which completely change prognosis of these patients, showing high rate and long-lasting responses. However, many cases still do not respond to CAR-T cells or relapse after the treatment or are not eligible to that kind of therapy. In this thought setting of MCL patients, next-generation therapies are emerging, such as new non-covalent BTK-i molecules, and novel monoclonal antibodies (MAB), which represent a heterogeneous group of agents, including naked antibodies, immunotoxins and T-cell engaging molecules. The impact of these agents is expected to be broad initially on R/R disease, but subsequently also in early treatment lines.
The aims of this review are to explore the main therapeutic strategies emerging in the context of MCL patients, who failed or are not eligible to CAR-T cells treatment, focusing on the most relevant therapeutic drugs and above all on the different monoclonal antibodies.
